Merck: molnupiravir supply agreement with UNICEF
(CercleFinance.com) - Merck (MSD outside North America) and Ridgeback Biotherapeutics today announced that they have signed a long-term supply agreement with UNICEF to facilitate broad global access to molnupiravir, their investigational oral antiviral drug for Covid-19.
Under the agreement, Merck will allocate up to three million doses of molnupiravir to UNICEF throughout the first half of 2022 for distribution in more than 100 low- and middle-income countries in accordance with regulatory approval.
As a reminder, the healthcare group is developing molnupiravir in collaboration with Ridgeback Biotherapeutics and has been approved for use in more than 10 countries, including the US, UK, Japan and Taiwan.
Copyright (c) 2022 CercleFinance.com. All rights reserved.